CatSci, a medicines development partner, has acquired Reach Separations, a specialist chromatography provider.
The acquisition was supported by Keensight Capital, a private equity manager focused on pan-European Growth Buyout investments.
CatSci's novel end-to-end chromatography offering
With a footprint across the UK and France, Reach Separations specialises in chromatography for the purification and analysis of chiral and achiral therapeutics.
The company can support businesses from the discovery chromatography stage to large scale supercritical fluid chromatography (SFC) for chiral purification and impurity isolation.
The acquisition of Reach Separations will bolster CatSci’s customer access to chromatography services, aiding them in the drug development process from end-to-end.
Reach’s SFC and HPLC (high-performance liquid chromatography) instrumentation provides a range of screening options and problem-solving capabilities, further supporting the combined company’s customer base.
This acquisition comes off the back of CatSci’s endeavours to grow its chemistry, manufacturing and control capabilities to boost its credentials as a manufacturing solutions provider.
CEO at CatSci, Dr Ross Burn commented: “The need for solving complex analytical problems while meeting the ever-evolving regulatory demands is growing alongside the development of new modalities, such as oligonucleotides, TACs (Targeting Chimeras), and glues. Joining forces with Reach gives our customers access to end-to-end coverage of the analytical development lifecycle, taking them from discovery through to GMP manufacture, and ultimately enabling them to help patients in need.’’
[Photo credit: Reach Separations]
